Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
La FDA informa cambios permanentes en el color de la piel relacionados con el uso del parche Daytrana (sistema transd érmico de metilfenidato) para el tratamiento del ADHD
[06-24-2015] La Administraci ón de Alimentos y Medicamentos (FDA) de los Estados Unidos advierte que el uso del parche Daytrana (sistema transdérmico de metilfenidato) para el tratamiento del Trastorno por Déficit de Atención e Hiperactividad (ADHD, por sus siglas en inglés) puede causar pérdida perm
Source: FDA Center for Drug Evaluation and Research - What's New - August 25, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
Listen to an audio podcast of the May 11, 2023, FDA Drug Safety Communication on warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
Source: FDA Drug Safety Podcasts - May 31, 2023 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions.
The FDA is requiring updates to the Boxed Warning and other information to ensure the prescribing information is made consistent across the entire class of these medicines to address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants.
Source: FDA Center for Drug Evaluation and Research - What's New - May 26, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years
ADHD affects an estimated 10 million adults in the U.S.
ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical...
Source: Drugs.com - New Drug Approvals - April 29, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Miami, FL and Jersey City, NJ - March 23, 2022 --Noven Pharmaceuticals, Inc., awholly-ownedsubsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Xelstrym (dextroamphetamine)...
Source: Drugs.com - New Drug Approvals - March 23, 2022 Category: Drugs & Pharmacology Source Type: news
Azstarys (Serdexmethylphenidate and Dexmethylphenidate Capsules) - updated on RxList
AZSTARYS is a central nervous system stimulant prescription medicine used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. Learn about uses, dosages, side effects, drug interactions, and others.
Source: RxList - New and Updated Drug Monographs - January 19, 2022 Category: Drugs & Pharmacology Source Type: news
Dealing with ADHD: What You Need to Know
Studies show that the number of children being diagnosed with ADHD continues to increase. Learn to recognize and treat ADHD in kids and adults.
Source: FDA Center for Drug Evaluation and Research - What's New - December 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Tris Pharma Announces FDA Approval of Dyanavel XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD
In a clinical study in adults, Dyanavel XR tablets demonstrated bioequivalence to Dyanavel XR (amphetamine) extended-release oral suspension.
ADHD patients taking Dyanavel XR oral suspension can conveniently switch to the same dose of Dyanavel XR...
Source: Drugs.com - New Drug Approvals - November 5, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Qelbree (viloxazine) for the Treatment of ADHD
ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)...
Source: Drugs.com - New Drug Approvals - April 2, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Azstarys (serdexmethylphenidate and dexmethylphenidate) Capsules for the Once-Daily Treatment for ADHD
CELEBRATION, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Approvals - March 2, 2021 Category: Drugs & Pharmacology Source Type: news
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)...
Source: Drugs.com - New Drug Applications - February 8, 2021 Category: Drugs & Pharmacology Source Type: news
Types of ADHD Medications
Title: Types of ADHD MedicationsCategory: MedicationsCreated: 1/31/2005 12:00:00 AMLast Editorial Review: 11/23/2020 12:00:00 AM
Source: MedicineNet Medications General - November 23, 2020 Category: Drugs & Pharmacology Source Type: news
Burden of ADHD substantial in Denmark
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)...
Source: Drugs.com - New Drug Applications - November 11, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults
Source: FDA Center for Drug Evaluation and Research - What's New - June 15, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
